Stockscreener 앱 받기
48.40
0.14%
0.07
시간 외 거래:
48.60
0.20
+0.41%
전일 마감가:
$48.33
열려 있는:
$48.14
하루 거래량:
11.77M
Relative Volume:
5.16
시가총액:
$7.59B
수익:
$1.17B
순이익/손실:
$150.71M
주가수익비율:
51.49
EPS:
0.94
순현금흐름:
$245.03M
1주 성능:
+3.46%
1개월 성능:
-4.16%
6개월 성능:
-35.77%
1년 성능:
-37.35%
1일 변동 폭
$47.23
$49.02
1주일 범위
$47.23
$49.02
52주 변동 폭
$46.01
$83.62
바이오-테크네 Stock (TECH) Company Profile
명칭
Bio Techne Corp
전화
(612) 379-8854
주소
614 MCKINLEY PL N E, MINNEAPOLIS, MN
TECH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
48.40 | 7.33B | 1.17B | 150.71M | 245.03M | 0.94 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
바이오-테크네 Stock (TECH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-09 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-08 | 개시 | Scotiabank | Sector Outperform |
| 2024-02-02 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-07 | 개시 | UBS | Buy |
| 2023-08-28 | 개시 | William Blair | Outperform |
| 2023-01-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | 업그레이드 | Stifel | Hold → Buy |
| 2021-01-25 | 재확인 | The Benchmark Company | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | 개시 | Atlantic Equities | Overweight |
| 2020-07-15 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-14 | 개시 | The Benchmark Company | Buy |
| 2020-01-08 | 재개 | Stephens | Overweight |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-07-02 | 업그레이드 | Janney | Neutral → Buy |
| 2019-01-14 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2018-10-17 | 개시 | Goldman | Neutral |
| 2018-06-15 | 개시 | Argus | Buy |
| 2017-07-13 | 개시 | Wells Fargo | Market Perform |
| 2017-02-09 | 개시 | Citigroup | Buy |
| 2017-01-18 | 개시 | Deutsche Bank | Buy |
| 2016-11-10 | 재개 | Leerink Partners | Outperform |
| 2015-01-21 | 재확인 | Robert W. Baird | Outperform |
| 2013-09-20 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
모두보기
바이오-테크네 주식(TECH)의 최신 뉴스
Bio-Techne stock price target cut to $65 by Argus - Investing.com
Demystifying Bio-Techne: Insights From 7 Analyst Reviews - Benzinga
Wells Fargo Initiates Coverage on Bio-Techne (TECH) with Overweight Rating | TECH Stock News - GuruFocus
Argus Adjusts Price Target on Bio-Techne to $65 From $90 - marketscreener.com
Wells Fargo starts Bio-Techne with Overweight, $59 target - Investing.com
Wells Fargo starts Bio-Techne with Overweight, $59 target By Investing.com - Investing.com India
Wells Fargo Initiates Bio-Techne at Overweight With $59 Price Target - marketscreener.com
Bio-Techne Corporation (TECH): A Bull Case Theory - Insider Monkey
Bio-Techne Corporation: An Insight Into The Pharmaceutical Market Dynamics & China's Economic & Regulatory Environment! - Smartkarma
Is Bio-Techne Stock The Right Pick For Your Portfolio Now? - Barchart.com
Is Bio-Techne Stock the Right Pick for Your Portfolio Now? - Nasdaq
Bio-Techne Sets Triple Conference Appearance: William Blair, Jefferies, and Goldman Sachs in June - Stock Titan
Bio-Techne to Present at Investor Conferences - PR Newswire
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MSN
Cetera Investment Advisers Sells 887 Shares of Bio-Techne Co. (NASDAQ:TECH) - Defense World
Do Wall Street Analysts Like Bio-Techne Stock? - MSN
(TECH) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Bio-Techne (NASDAQ:TECH) Rating Increased to Buy at StockNews.com - Defense World
Ex-Dividend Reminder: Bio-Techne, First Hawaiian and Affiliated Managers Group - Nasdaq
Wednesday Sector Laggards: Healthcare, Materials - Nasdaq
What Makes Bio-Techne Corporation (TECH) a Compelling Addition? - Insider Monkey
ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA) - Quantisnow
Bio-Techne at BofA Securities 2025: Strategic Growth Amid Challenges By Investing.com - Investing.com Nigeria
Bio-Techne at BofA Securities 2025: Strategic Growth Amid Challenges - Investing.com
Transcript : Bio-Techne Corporation Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10 - marketscreener.com
Waters Corporation, Avantor, Azenta, Bio-Techne, and Elanco Stocks Trade Up, What You Need To Know - Yahoo Finance
Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025 - The Malaysian Reserve
Bio-Techne to Showcase Next-Generation Solutions for Gene and Ce - GuruFocus
UBS Group Cuts Bio-Techne (NASDAQ:TECH) Price Target to $70.00 - Defense World
When the Price of (TECH) Talks, People Listen - news.stocktradersdaily.com
StockNews.com Downgrades Bio-Techne (NASDAQ:TECH) to Hold - Defense World
Bio-Techne (TECH) Target Price Lowered to $70 by UBS Analyst | T - GuruFocus
UBS Adjusts Price Target on Bio-Techne to $70 From $95, Maintains Buy Rating - marketscreener.com
Bio-Techne outlines 2025 growth drivers with NIH uncertainty and strong Protein Sciences performance - MSN
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Corp (TECH) - GuruFocus
Bio-Techne, Kytopen collaborate on integrated cellular engineering workflow - TipRanks
Bio-Techne (TECH) Target Price Lowered by RBC Capital | TECH Sto - GuruFocus
Bio-Techne (TECH) Target Price Lowered by RBC Capital | TECH Stock News - GuruFocus
Benchmark Adjusts Bio-Techne Price Target to $75 From $95 - marketscreener.com
Bio-Techne (TECH): Benchmark Analyst Lowers Target Price but Maintains Buy Rating | TECH Stock News - GuruFocus
BIO-TECHNE (TECH): Analyst Maintains Hold Rating, Lowers Price Target | TECH Stock News - GuruFocus
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference - StreetInsider
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Eng - GuruFocus
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing | TECH Stock News - GuruFocus
Bio-Techne price target lowered to $63 from $72 at RBC Capital - TipRanks
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing - Stock Titan
Bio-Techne Corporation (NASDAQ:TECH) Q3 2025 Earnings Call Transcript - Insider Monkey
Bio-Techne Third Quarter 2025 Earnings: EPS Misses Expectations - simplywall.st
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference | TECH Stock News - GuruFocus
RBC Cuts Price Target on Bio-Techne to $63 From $72, Keeps Sector Perform Rating - marketscreener.com
Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global ... - Yahoo Finance
바이오-테크네 (TECH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):